Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.090
-0.110 (-9.17%)
At close: Mar 13, 2025, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Mar 13, 2025, 7:02 PM EST
Enlivex Therapeutics Employees
Enlivex Therapeutics had 71 employees as of December 31, 2021. The number of employees increased by 21 or 42.00% compared to the previous year.
Employees
71
Change (1Y)
21
Growth (1Y)
42.00%
Revenue / Employee
n/a
Profits / Employee
-$266,662
Market Cap
23.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
ENLV News
- 9 days ago - Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - GlobeNewsWire
- 10 days ago - Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - GlobeNewsWire
- 23 days ago - Enlivex Issues Urgent Statement on Fraudulent News Dissemination - GlobeNewsWire
- 2 months ago - Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 3 months ago - Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - GlobeNewsWire
- 3 months ago - Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - GlobeNewsWire
- 3 months ago - Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - Accesswire
- 4 months ago - Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis - GlobeNewsWire